










Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/134760                                                         
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
Human African trypanosomiasis:
current status and eradication efforts
Christopher N. Davis1,2, Kat S. Rock1,2, Matt J. Keeling1,2,3*
1 Zeeman Institute (SBIDER), University of Warwick, Coventry, CV4 7AL, UK
2 Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
3 School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK
* Corresponding author: M.J.Keeling@warwick.ac.uk
Abstract
Epidemics of human African trypanosomiasis (HAT) in the 20th century led to millions of deaths.
However, since the start of the twenty-first century, there is been a continued decline in the number
of reported cases, due to increased investment and prioritisation of control efforts. Systematic screen-
ing of at-risk areas and widespread access to increasingly advanced diagnostics and treatments, along
with much improved vector control, have all helped to make disease elimination achievable in the near
future. Despite the progress, the danger of disease resurgence is well-known for HAT and continued
surveillance and treatment availability is essential. Additionally, many uncertainties regarding HAT
transmission remain and combine to make potential disease eradication a complete unknown.
Keywords: human African trypanosomiasis, elimination, diagnostics, treatment, mathematical mod-
elling
Review methodology: We searched CAB Abstracts and Google Scholar for relevant articles us-
ing the keywords human African trypanosomiasis, sleeping sickness, and elimination. We also used
references from these articles for additional relevant material.
Introduction1
Human African trypanosomiasis (HAT), commonly known as sleeping sickness, is a vector-borne disease2
affecting humans in sub-Saharan Africa. It is caused by parasitic protists of the species Trypanosoma3
brucei, of which there are two subspecies that can infect humans: gambiense and rhodesiense. Both4
types of the parasite are typically transmitted to humans by infected tsetse (genus Glossina), a large5
biting fly that inhabits affected regions. The diseases caused by these infections are generally fatal6
without treatment [1] and it is estimated that in the last 100 years HAT has been responsible for7
millions of deaths [2].8
Historically HAT was endemic in 36 countries of sub-Saharan Africa, with most gambiense human9
African trypanosomiasis (gHAT) cases occurring in West and Central Africa and most rhodesiense10
human African trypanosomiasis (rHAT) cases occurring in East Africa (see Figure 1) [3]. The disease11
distribution across these countries is highly focal [2, 4], around locations containing the epidemiological12
factors conducive for transmission of infection. This spatially heterogeneous clustering of incidence is13
predominantly attributed to the habitat of the vector (tsetse), but is notable since disease prevalence14
can vary greatly over short distances and even between neighbouring villages [5]. In general, rHAT15
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Figure 1: Map of the 36 historically HAT-endemic countries. 24 countries are gHAT endemic and 13
are rHAT endemic, including Uganda, which is endemic with both.
is considered to be a predominantly zoonotic disease with human cases as a result of spill-over from16
animal infections. In contrast, humans are far more involved with the transmission cycles of gHAT17
where there is less evidence of zoonotic transmission and the role of animals remains ambiguous [6].18
gHAT is the more widespread of the two diseases, causing 98% of all reported infections in the last 1019
years of data (2009–2018) [7]; the Democratic Republic of the Congo (DRC) is the country with the20
highest proportion of gHAT cases with 82% in this period [7].21
Historical cases and control strategies22
The first accurate medical report of HAT was published in 1734 [8]. In 1896–1906 a large-scale epidemic23
of HAT was recorded which caused an estimated 800,000 deaths across the Congo basin and Uganda24
[9], which was coincident with European colonisation of the region and severe droughts. However, it25
was not until the early twentieth century that cases were routinely recorded [10] (Figure 2).26
Historical control of HAT utilised three main mechanisms that, although much refined, still form27
the basis of modern control. In 1905, the first drugs effective in treating HAT were discovered. These28
were organic arsenicals, which had mixed benefits: while successful in reducing parasitaemia, they29
were less effective for patients in Stage 2 of the disease and were also relatively toxic to the patients30
[11]. In the 1920s Euge`ne Jamot devised the test and treat principle, using mobile teams to cover the31
highest possible proportion of the population at risk [12]. Finally, as early as 1911 systematic vector32
control was also introduced to the island of Principe, using primitive tsetse traps [10]. Despite this33
early progress, control measures declined after 1953, and through to the end of the twentieth century,34
leading to a resurgence of cases.35
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Figure 2: Cases and number of people screened for HAT reported to the World Health Organization
between 1939 and 2018. Data is collated from WHO reports and WHO’s Global Health Observatory
data repository (cases and screening 1939–1998 [13], cases 1999–2018 [7], and screening 2000–2016
[15]).
Current epidemiology and elimination targets36
The number of annual reported HAT cases has varied dramatically in the last century as a consequence37
of different levels of investment in control [13] (Figure 2). However, since the late 1990s, HAT control38
has been more actively prioritised, with coordination between the World Health Organization, national39
HAT control programmes, funding agencies, industrial partners, and non-governmental organisations40
[14]. This has improved the support of control activities within HAT-endemic countries with better41
surveillance and access to diagnostic tools and treatments [2]. This reinvestment, coupled with ad-42
vancements in diagnostics and drugs to treat the infection, as well as plausible elimination strategies,43
has led to a steep decline in gHAT cases (Figure 2). In 2018, the number of reported HAT cases44
dropped below 1,000 cases, from a recent peak of 38,000 cases in 1998 [7].45
The Neglected Tropical Diseases (NTD) Roadmap, published in 2012, identified HAT as a candidate46
for elimination as a public health problem [16]. The was formalised as a goal in 2013, with the47
elimination definition, comprising of two global indicators, updated in 2017 to: (i) fewer than 2,00048
reported cases per year, and (ii) reducing the area at risk of reporting more than 1 case per 10,00049
people per year by 90% as compared to the baseline for 2000–2004. The Roadmap is due to be updated50
in 2020 and is proposed to include the goal of zero reported gHAT cases by 2030 [3, 17, 18].51
The first indicator for elimination as a public health problem is very likely to be met by 2020, since52
it is currently being achieved, with 977 cases reported to WHO (of which 953 were gHAT) in 2018, well53
below the target of 2,000 [7]. The second indicator is more challenging to assess; in 2012–2016, 280,00054
km2 of land was estimated to be at moderate risk or higher of HAT, a reduction of 61% compared to55
the baseline 790,000 km2 from 2000–2004 [15]. Therefore, the 90% reduction was not met by 2016, but56
the progress is encouraging, with a continued decline in the at-risk area; the size of this area was close57
to the milestone aim of 230,000 km2 for 2012–2016 [16]. It is expected that these downward trends are58
indeed reflecting a real decline in transmission, rather than simply under-reporting, since the number59
of health facilities providing HAT surveillance, diagnosis and treatment is increasing [15].60
There is less evidence that the 2030 elimination of gHAT transmission target [17] will be met, but61
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it remains an important aspirational goal to ensure that progress is sustained and that the previous62
mistakes of early cessation of HAT programmes are not repeated in the twenty-first century [19].63
Intervention approaches64
To attain the targets set by WHO and break the transmission cycle, HAT interventions need to be65
applied effectively at all levels, understanding the geography, the community and field workers, the66
technology, and the governance [20]. However, to be able to implement intervention strategies success-67
fully, there also needs to be adequate surveillance; this allows both for long-term disease monitoring68
and early identification of outbreaks [21]. HAT surveillance is recorded as screening and incidence69
data by the WHO in the Atlas of Human African Trypanosomiasis [22, 23]. This is a systematic70
approach of collating the number of new cases in villages across the endemic areas in each year, as well71
as the number of people screened for HAT and a census estimate. This data allows for the production72
of disease-risk maps, monitoring, planning of future surveillance and data for modelling and making73
future predictions [24].74
Active Screening75
Since there is no vaccine or chemoprophylaxis for HAT [25], case control for gHAT is primarily through76
direct case detection by mass screening, followed by confirmation and treatment [26]. This has widely77
been considered to be the most effective method of control, even since the early twentieth century78
[27–29]. Its impact on reducing the underlying number of infections is also supported by mathematical79
modelling [30].80
Active screening is implemented by the operations of small mobile teams including microscopists,81
secretaries, drivers, messengers, guards, and health workers, who travel directly to villages in the HAT-82
endemic areas in four-wheel drive vehicles (or boats) and aim to test full populations for the infection83
through mass screening [31]. The region a mobile team can cover may include a population of up to84
800,000, and teams typically travel for twenty days each month to conduct active screening, staying85
for multiple days in some large villages to ensure the available population is screened [31]. The choice86
of villages visited is dependent on the history of screening and cases in the village and area, cases from87
nearby health centres and local information [31]. Other predictive methods to identify at-risk villages88
are being devised [32].89
For active screening programmes to be effective a high screening coverage is important in all villages90
to ensure the detection and treatment of those infected and prevent onward transmission. This requires91
a detailed knowledge of the area with sensitisation ahead of an active screening, to ensure that the92
village is ready for the maximum possible number of people willing and available to be screened and93
not on an inconvenient day, such as when there is a market [33]. There also needs to be low drug94
toxicity, low cost to the patients and some level of privacy to achieve high attendances and treatment95
uptakes [29, 34, 35].96
There is limited evidence for how frequently these active screenings should occur and when they97
should stop if no cases are found. Van Nieuwenhove [36] recommends three repeated screening rounds98
with one year intervals, while Simarro et al. [37] used six month intervals. The current WHO rec-99
ommendation is for yearly screening with three years of zero case reporting before stopping active100
screening in the village [26]. There have been many calls for the need to maintain active screening,101
even when no cases are observed [38, 39], particularly given the feedback between surveillance and con-102
trol [40]. Recent mathematical modelling has suggested that infection is expected to persist for long103
periods, with no new infections detected for multiple years to have any certainty of local elimination104
[41]. Indeed, multiple years of active screening without case detections is a valuable measure of the105
likelihood that elimination of transmission has been achieved [42].106
In low-prevalence settings, due to consistent under-representation of certain demographics [35], tar-107
geted door-to-door screening can be more cost-effective and less labour-intensive if there is knowledge108
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of suspected cases, alongside the availability of diagnostic tests and treatments for individuals suffering109
symptoms. Indeed, door-to-door screening has been found to detect significantly more HAT cases than110
standard active screening [43]. In locations where the terrain is difficult to traverse, active screening111
is also carried out by light mobile teams using motorbikes [44].112
Passive Detection113
To better detect cases, there needs to be additional support for those that are not reached by active114
screening. As such, passive surveillance provides fixed health centres with the capacity and tools115
required to test and treat for HAT [45]. This is crucial in areas with low transmission intensity that116
will not be targeted in active screening [46], which will become more common as total case numbers117
fall [14]. It also ensures that individuals who miss active screening events or receive a false negative118
result in previous active screening, can still access diagnosis and treatment. These facilities need to119
be suitably equipped, such that infections are recognised promptly [47, 48]. Since passive surveillance120
relies of individuals to self-present to these health centres, a high proportion of them will be in the late121
stage of the disease, with significant symptoms [49]. The ability to access facilities where HAT can be122
rapidly diagnosed shortens the time between infection and treatment, reducing potential transmission123
opportunities. Indeed modelling has suggested there is great potential in improving rates of passive124
case detection [50].125
Vector Control126
Since gHAT is largely considered an anthroponosis, control has heavily relied on active and passive127
surveillance rather than considering the tsetse [14]; however, if vector control can reduce the number of128
tsetse, there will be fewer flies able to become infected, and hence a reduction in HAT transmission [51].129
Vector control is frequently a staple component of other vector-borne disease intervention strategies,130
such as malaria and dengue, due to its potential to avert transmission. Modelling has supported this131
hypothesis for gHAT, predicting that in many areas including vector control would consistently avert132
more infections that other intervention strategies [52, 53] and strategies without vector control may133
be insufficient to meet the 2030 elimination of transmission target [30, 54, 55].134
Tsetse control can be implemented by traps, targets, insecticide-treated cattle, aerial spraying,135
or sterile insect release [56]. One current strategy showing considerable potential is the use of ‘tiny136
targets’ [25]. These are small blue squares of cloth attached to a square of mesh impregnated with137
the insecticide, deltamethrin. They are attached to a frame and either planted in the ground or hung138
from vegetation. Tsetse are attracted to the blue colour, circle the cloth and come into contact with139
the insecticide, resulting in their death [57–61]. These targets are both highly effective and easier to140
deploy that traditional devices [51] in settings where livestock density is low. In regions with higher141
cattle ownership, restricted application of insecticides can also be a cost-effective approach to reduce142
tsetse populations [62].143
The two main drawbacks of vector control until recently were the expense [25] and the associated144
logistics of repeatedly deploying multiple control. However, with developments in insecticide-treated145
targets and traps [25, 59, 63], tsetse control can now be considered more cost-effective [64]. The small146
size has helped reduce costs, while remaining effective [25]. Furthermore, tsetse control is species-147
specific to tsetse and does not negatively impact the environment, since tsetse are not a key species in148
the food chain. Therefore, it can be considered ethically defensible, as human deaths are averted [65];149
the objective is for local reduction of tsetse in HAT foci to interrupt transmission, rather than global150
eradication of the fly [66].151
‘Tiny targets’ have been introduced in several HAT foci, such as Guinea, Uganda Chad where152
reductions in the tsetse population of 80% in 18 months [67], 90% in 12 months [66], and 99% in 4153
months [53] have been observed respectively. Furthermore, no gHAT cases have been found in areas154
where ‘tiny targets’ were deployed in North West Uganda [68]. When challenges are presented to155
health services, tsetse control is often easier to maintain than traditional medical interventions. For156
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example, when active screening was postponed in Guinea due to the 2014–2016 Ebola outbreak, a rise157
in gHAT prevalence was observed; however, in the area where tsetse control had been implemented, no158
cases were found. Vector control is also now part of HAT control strategy in some high-burden areas159
in the DRC, the country with the highest HAT burden [7, 69].160
Diagnostics161
Medical treatment of HAT patients can cure them of the infection and so prevent suffering and potential162
death, however, early detection of the infection will also reduce the duration a person is infectious and163
able to transmit the infection to biting tsetse. Therefore, accurate diagnostic tools are essential to164
identify early stages of the infection and both prevent the severe symptoms for the individual and165
reduce further transmission to the population. Different diagnostics are available as field-applicable166
and laboratory-bound tests.167
The most commonly used and reliable test for gHAT infection in the field is the card agglutination168
test for trypanosomiasis (CATT) [70]. This is a serological test developed in the 1970s, which uses169
blood collected from a finger prick, plasma, or serum [71]. The test is most suited to be carried out170
by mobile teams in active screening since it is relatively quick, inexpensive and reliable. However, the171
test does require an electricity supply, a cold chain and trained personnel [72]. A positive CATT test172
requires additional parasitological validation to visibly detect the presence of parasites by microscopy173
for HAT confirmation [73].174
More recently, rapid diagnostic tests (RDTs) have been available to screen for gHAT. These tests175
have an important role in the fixed passive detection health centres, since they do not require electricity176
and are instrument-free [74]. This means rural hospitals, that are often ill-equipped, can still screen177
for HAT, and hence RDTs have been widely distributed in remote endemic areas [74–76]. While these178
tests are being developed to have both high sensitivity and specificity (comparable to CATT) [77–82],179
in areas where the infection numbers are low, the number of false positives from RDTs can far outweigh180
the number of true positives, resulting in a very low positive predictive value [2, 83]. Cost-effectiveness181
analysis has suggested RDTs could be more cost-effective than CATT in both mobile and fixed health182
facilities [74].183
For laboratory-bound tests, the trypanolysis test is a confirmatory test with extremely high speci-184
ficity, such that positives from other tests can be verified and thus the patients treated. However, this185
test is expensive to perform and can only be done in selected laboratories in Europe and Africa [26].186
Notwithstanding this, the trypanolysis test is particularly useful in the context of elimination since187
its high specificity means it can be used as a surveillance tool to identify areas which are disease-free188
[84, 85]. Enzyme-linked immunosorbent assays (ELISAs) can also be used as confirmatory tests with189
high specificity, but are time-consuming, expensive and need to be performed in large batches [86].190
Molecular tests have also been developed to detect T. b. gambiense [87] and exhibit high sensitivities191
and specificities. The fact these tests are not directly applicable in the field yet, however, means the192
direct benefit remains limited [75, 88].193
Rhodesiense HAT currently has no field-applicable serodiagnostic test [2], however the more obvious194
symptoms and high levels of parasitaemia make this less crucial for detection of the infection [26].195
Treatment196
Classically, because of the very different severity of symptoms and location of trypanosomes in the197
two stages of HAT, treatments are generally stage specific [89]. The earlier HAT is treated, the better198
prospects for the patient; drugs for Stage 1 will not cure a patient in Stage 2, and drugs for Stage 2199
are unnecessarily toxic for patients in Stage 1. Hence staging is traditionally an important first step in200
determining whether the parasite has passed the blood–brain barrier into the central nervous system.201
This relies on a lumbar puncture to collect cerebrospinal fluid for the counting of white blood cells and202
to ascertain whether trypanosomes are present [90].203
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Until recently, the drugs used to treat Stage 1 infection were pentamidine or suramin [91]. Pen-204
tamidine has a high effacacy in treating gHAT and is administered intramuscularly for seven days,205
with generally minimal ill-effects [2]. Suramin is effective too, but is only used for rHAT as the slow206
intravenous infusion is more difficult to manage and the side-effects more frequent [2].207
For Stage 2, the first-line treatment is nifurtimox–eflornithine combination therapy (NECT) (ni-208
furtimox is delivered orally and eflornithine delivered intravenously) [92, 93]. This is an agressive209
treatment with common side-effects including abdominal pain, vomiting and headaches, with a high210
probability of a successful treatment [2]. The alternative, melarsapol, is now restricted to Stage 2211
rHAT, due to the frequency of life-threatening reactions it can induce [94].212
All five of the drugs are donated by manufacturers to WHO, who is able to freely who are able to213
freely distribute them across HAT-endemic countries [2].214
In addition to these drugs, fexinidazole [95], an oral drug that is taken for ten days, was recently215
included in WHO guidelines for gHAT treatment [96] and approved for use in the DRC in December216
2018 [97]. This drug is effective in treating both stages of gHAT, when the symptoms are not overly217
severe [98]; so eliminating the need for a painful lumbar puncture to determine the infection stage,218
and simplifying the treatment process whilst improving access to care [69, 97]. However, it is notable219
that a lack of stage determination provides less information for subsequent surveillance and can reduce220
the accuracy of recommendations from predictive models [99]. Fexinidazole appears less effective than221
NECT in treating late Stage 2 patients however [96], and the effect on parasites in the skin is still222
unknown [100]. The safety profile of fexinidazole is not sufficient to consider treatment without parasite223
confirmation as part of the diagnostic algorithm.224
Another drug, acoziborole [101] is currently being trialled as a one-day, one-dose oral treatment for225
all gHAT patients. This could potentially revolutionise treatment due to the ease with which it would226
be delivered and has the potential to be administered to all at-risk populations based on RDT results,227
or even given to all high-risk individuals if suitable safety standards are met [100].228
Considering eradication229
There are many reasons to be optimistic about the eventual elimination of HAT: the declining trend230
in reported cases; the availability of accurate diagnostics; effective drugs that are freely donated; new231
diagnostics and drug being developed; and continuing operations to reduce infection numbers through232
both active and passive surveillance and tsetse control. However, as the case numbers decrease to very233
low levels, there will be more competition for funding with other diseases [102, 103] and activities will234
have to continue to avoid resurgence [14]; in addition other factors may emerge that were undetectable235
at high prevalences but could pose problems for elimination and eventual eradication.236
Firstly, all figures for HAT infections are based on reported case numbers and it is expected that237
the true number infected will be much higher. For rHAT in particular, with very low case numbers,238
there has been a decrease in HAT-skilled staff, causing a decrease in awareness and hence reporting as a239
consequence [15]. There is also an issue with systematic non-participation in screening for gHAT, where240
sections of the population are likely to avoid being screened [35]. Data on the age and gender of screened241
participants could be used to determine which groups are not attending screening, although this is not242
routinely collated in an electronic format. Anecdotal evidence suggests working age individuals are the243
least likely to participate, as they may be away from the village working when active screening teams244
visit. From the perspective of elimination, this is particularly troubling since this group is also more245
likely to be working in the tsetse habitat, close to vegetation surrounding river. Hence, there could be246
a high-risk (core) group for infection never being tested – a hypothesis supported by fitting models to247
longitudinal active and passive case data to regions in DRC and Chad [30, 53]. If screening stops in248
areas where there are no identified cases, transmission could be sustained by such a core maintenance249
population, which could re-infect those who have partaken in active screening [6, 104].250
Without active surveillance that can reach high proportions of the at-risk populations, there is also251
the danger that gHAT could sustain itself in low numbers due to a possible asymptomatic reservoir of252
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humans [105]. It has been observed that some individuals infected with gHAT do not present symptoms253
for a long time and so will not seek medical attention or be detected, as they are unaware of the infection254
[1]. These individuals may have the trypanosomes surviving in their skin with no blood parasitaemia,255
which is difficult to screen for in large numbers [100]. However, the parasite can still be ingested by256
tsetse and so transmitted [6, 106, 107]; modelling has suggested treatment of these asymptomatic cases257
should be considered [108]. Gaps in active screening coverage for at-risk populations may also hinder258
elimination programmes [109], with high coverage needed to be maintained to prevent a decrease in259
detected cases being due to a decrease in screening effort [110].260
Movement of infected people into disease-free areas should also be considered in intervention plan-261
ning [111], as this can lead to recrudescence [41]. This is especially important in former-endemic areas,262
where HAT control is no longer considered a priority and high influxes of refugees, could be a perfect263
environment for parasite transmission [112].264
Finally, even if the gambiense form of the infection was eliminated from humans, there is the265
possibility that the transmission cycle could be preserved through animal reservoirs [113]. This is266
certainly the case for rHAT [2], but while T. b. gambiense infection exists in animals, it remains267
unclear if animal hosts able to sustain infection or are likely to re-infect human populations [114].268
Modelling has suggested that the existence of an animal reservoir was a requirement for continued269
transmission in a gHAT focus in Cameroon [115], while other studies have demonstrated there is lack270
of evidence to draw definite conclusions [30, 105]. Spraying livestock could prevent some transmission271
in domestic animals, but pockets of infected wild animals could still pose a problem. The existence of272
a T. b. gambiense infected animal on the island of Luba, where there have been no reported human273
cases since 1995 [116], also provokes wider questions about persistence in the absence of human cases274
and potential reintroduction from the animal reservoir [6, 117]. To achieve rHAT elimination, there275
will need to be multisectoral (One Health) cooperation, with impetus for improved surveillance of276
infection in both humans and animals [118].277
Conclusion278
HAT cases have declined substantially in the twenty first century due to considerable efforts to eliminate279
the diseases [7]. Elimination of transmission of gHAT has also been shown to be cost-effective, with280
economic benefits greater than the costs [102, 119]. Efforts need to be maintained to sustain the281
current decline in cases, with continued investment in diagnostics and treatment, as well as their282
implementation in active and passive surveillance, and tsetse control; even recent interruption of283
interventions has been known to lead to an increase in cases [120]. For rHAT, there are now only tens284
of cases, but completely eliminating transmission could be less achievable due to substantial zoonotic285
transmission. Despite over a century of study and data, there still remain key unknowns concerning286
the biology and epidemiology which influence the likely success of the proposed elimination of these287
diseases [6, 15].288
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